PROTEOSTASIS THERAPEUTICS IN's ticker is PTI and the CUSIP is 74373B109. A total of 52 filers reported holding PROTEOSTASIS THERAPEUTICS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $845,000 | -68.7% | 108,000 | -50.9% | 0.06% | -68.0% |
Q4 2016 | $2,697,000 | -21.4% | 220,000 | 0.0% | 0.18% | -16.3% |
Q3 2016 | $3,430,000 | +41.4% | 220,000 | +10.0% | 0.21% | +41.2% |
Q2 2016 | $2,426,000 | +25.8% | 200,000 | 0.0% | 0.15% | +37.0% |
Q1 2016 | $1,928,000 | – | 200,000 | – | 0.11% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 3,804,027 | $17,803,000 | 2.95% |
HARBOURVEST PARTNERS LLC | 440,627 | $2,062,000 | 0.89% |
NEA Management Company, LLC | 3,556,778 | $16,646,000 | 0.61% |
Rock Springs Capital Management LP | 450,000 | $2,106,000 | 0.11% |
Bain Capital Public Equity Management, LLC | 263,498 | $1,233,000 | 0.07% |
ELEMENT CAPITAL MANAGEMENT LLC | 65,973 | $309,000 | 0.06% |
Hillhouse Capital Management | 865,923 | $4,053,000 | 0.06% |
SABBY MANAGEMENT, LLC | 125,151 | $586,000 | 0.04% |
Marshall Wace North America L.P. | 684,124 | $3,421,000 | 0.02% |
FNY Partners Fund LP | 20,127 | $94,000 | 0.02% |